key: cord-1023761-s74bpm85 authors: Zhao, Yuxi; Shu, Rui; Liu, Jiang title: The development and improvement of ribonucleic acid therapy strategies date: 2021-09-14 journal: Mol Ther Nucleic Acids DOI: 10.1016/j.omtn.2021.09.002 sha: 8340dda57a94762e1d7033cc67360143229cbecc doc_id: 1023761 cord_uid: s74bpm85 The biological understanding of RNA has evolved since the discovery of catalytic RNAs in the early 1980s and the establishment of RNA interference (RNAi) in the 1990s. RNA is no longer seen as the simple mid-product between transcription and translation, but potential molecules to be developed as RNA therapeutic drugs. RNA-based therapeutic drugs have gained recognition due to their ability to regulate gene expression and perform cellular functions. Various nucleobase, backbone, and sugar-modified oligonucleotides have been synthesized, as natural oligonucleotides with some limitations such as poor low nuclease resistance, binding affinity, poor cellular uptake and toxicity, which affect their use as RNA therapeutic drugs. In this review, we briefly discuss different RNA therapeutic drugs and the internal connection, including antisense oligonucleotides, siRNA and miRNA, aptamers, saRNA, and RNA vaccines, we also discuss the important roles of RNA vaccines and their use in the fight against COVID-19. In addition, various chemical modifications and delivery systems used to improve the performance of RNA therapeutic drugs and overcome their limitations are discussed. As drugs, antibodies and small molecules mostly interact with proteins and display 35 therapeutic activities towards diseases on either small or large scales. Representing two 36 generations of drug therapy, antibodies and small molecules have exerted excellent effects 37 and contributed considerably to the development of human health. However, antibodies can 38 only recognize targets that are both druggable and secreted or extracellular, as intracellular 39 delivery is deficient. In addition, antibody drugs and small molecule drugs need to be 40 administered every few weeks, which may stimulate immunological responses and cause side 41 J o u r n a l P r e -p r o o f RNA therapy is a rapidly developing field with notable potential and its evolution should be 91 properly documented. In order to provide comprehensive summaries and unique insights into 92 RNA therapy, we will specifically analyze the development and mechanisms of RNA 93 therapeutic drugs. In addition, we will highlight the various chemical modifications and 94 delivery systems that are undertaken to improve stability and efficiency. RNA drugs are listed 95 in the order of discovery. (Fig. 1a ). In addition, DNA can be loaded to a virus or phage and enter cells indirectly, where 106 its transcript can recognize and bind to target mRNAs, inhibiting mRNA from 5' capping, 3' 107 polyadenylation, and splicing, ultimately terminating gene expression (Fig. 1b) . Broadly 108 speaking, antisense therapy includes ribozymes, but these will be discussed later. 9 According gene expression. In addition, by inserting an RNA-cleaving ribozyme sequence near the 112 targeted cleavage site, AONs can be designed to cleave specific sites in mRNAs. 10 113 AONs possess more potential action mechanisms and are easier to deliver intracellularly. 114 However, most AON drugs exert degradation effects on a one-to-one basis, which suggests 115 that one AON drug can only interact with a single mRNA molecule. Currently, there are 116 seven approved AON drugs (Table 1 6 , 11 ), and more than 50 candidates are in clinical trials. Dysregulated editing of adenosine-to-inosine (A-to-I) RNA is related to various cancers. 118 Tay et al. have recently deciphered the secondary structure of antizyme inhibitor 1 (AZIN1) 119 RNA, which is one of the best-studied A-to-I editing targets in cancer, by locating its editing 120 site complementary sequence (ECS). The ECS was shown to be an ideal target for abolishing 121 AZIN1 editing without affecting translation, while ASOs targeting the editing region of 122 AZIN1 caused substantial skipping of exon 11. The results demonstrated that AZIN1-123 targeting, ASO-based therapeutics may be applicable to a wide range of tumor types. 12 124 Spliceosome-mediated RNA trans-splicing (SMaRT), an antisense therapy that intervenes 125 at the posttranscriptional level, was first developed by Puttaraju et al. in 1999. 13 SMaRT 126 exploits the cell's own splicing machinery to trans-splice therapeutic coding sequences into 127 endogenous pre-mRNA targets, joining exons from different pre-mRNA transcripts to 128 generate a chimeric product. 14 The therapeutic coding sequences are delivered by artificially 129 engineered pre-mRNA trans-splicing molecules (PTMs). In order to induce the trans-splicing, 130 rather than the cis-splicing, reaction to produce the desired product a splicing domain and a 131 binding domain must be contained in the PTM. The most well-described SmaRT approach is SMaRT also finds its place in the treatment of infectious diseases. The diphtheria toxin 151 (DTA) chain has been trans-spliced onto the mRNA from hepatitis C (HCV) through 152 ribozyme-mediated 3'ER, which subsequently induces apoptosis. 21 By activating 153 MAPK/ERK, Herpes simplex virus type 1 thymidine kinase/ganciclovir (HSV-TK/GCV) can 154 induce cytotoxicity of retinoblastoma cells through autophagy inhibition. 22 GCV is a 155 thymidine kinase while HSV-TK can phosphorylate GCV to GCV-TP, which functions an 156 inhibitor of DNA synthesis competitive competing with guanine-5'-triphosphate. This suicide diseases with multifactorial etiologies, such as cancer, single gene repair has been able to 159 target mutated genes, such as p16 and p53, for correction and restoration of the function. 24, 25 160 Although synthesized antisense nucleic acids preferentially select the promoter or 161 translation initiation regions as their target sequences, their targets remain semi-random. The 162 accessibility of different regions is not equivalent, which may be related to the high-level 163 molecular folding of RNA molecules in the cell and the binding of RNA to protein factors. Ribozymes, catalytic RNA molecules that induce specific degradation of target mRNAs, 170 are also a category of RNA therapeutics. The discovery of catalytic RNAs was in the early 171 1980s, followed by a wave of research on nucleic acid-based inhibitors of gene expression. Simplified catalytic motifs were defined in the late 1980s and early 1990s, which rendered it 173 possible to chemically synthesize ribozymes, enabling these molecules to function as target-174 specific inhibitors of gene expression. Ribozymes act as enzymes that break or form covalent bonds, accelerating targeted 176 reactions with or without proteins. 27 There are more than ten ribozymes that mostly conduct 177 general acid-base reactions, although the detailed mechanisms vary. 28 The general base 178 induces deprotonation at 2'-OH to activate 2'-O -, wheras the general acid protonates the 5'-O 179 of the leaving group. The 3,5-phosphodiester bond at the cutting site is cleaved after the 180 reaction ends, with covalent bonds between 2'-Oand 3'-phosphoric acid emerging instead of 181 J o u r n a l P r e -p r o o f the mRNA being cut into two pieces. 29, 30 Gene expression is inhibited at the level of 182 translation, as mRNA is degraded (Fig. 1c) . Ribozymes exist naturally, however, they can also be artificially engineered to express and 184 target specific sequences in either cis (on the same nucleic acid strand) or trans (a 185 noncovalently linked nucleic acid) form. 31 The term "hammerhead" ribozyme was given to a 186 group of small self-cleaving ribozymes derived from single-stranded plant viroid RNAs. The 187 hammerhead ribozyme is 30 nt, and its simple structure makes it an excellent choice for the 188 design of trans-acting ribozymes. It can be engineered to cleave any target RNA by Watson-189 Crick base pairing. 32, 33 The "Hairpin" or "paperclip" is another plant-derived and self-190 cleaving ribozyme identified in the negative strand of tobacco satellite RNA. 34 RNase P is an enzyme that is widely found in humans and contains RNA and protein Currently, there are more than ten aptamer candidates in clinical trials (Table 3 , 308 https://www.clinicaltrials.gov/). More specifically, aptamers are single-stranded DNA or RNA molecules that bind proteins 310 with high specificity due to their stable three-dimensional shapes. 58 DNA and RNA aptamers 311 are typically generated through the process of systematic evolution of ligands by exponential The specificity of saRNA is closely related to the length of the dsRNA, which is usually 377 less than 30nt. A study has shown that neither truncated nor extended dsRNA can activate 378 translation. 66 Additionally, the 5' end of the saRNA is the key functional sequence. After 379 replacing the antisense nucleic acid strand at the 5'end of dsRNA with five base pairs, the 380 activating effect was completely lost, whereas the same replacement of base pairs at the 381 3'end and the middle region had no effect on activation. 66 To induce translation, interaction 382 between saRNAs and genes is necessary, whereas simple identification has little effect. For produced by the patient themselves (Fig. 3a) . In addition, the induced antigens are 439 synthesized by host cells in patients and rarely cause non-specific tumor immune responses. In addition, there is no risk of external gene integration into the host DNA (Fig. 3b) . The key advantage of mRNA is that it is convenient to synthesize once researchers know Most research into these ON analogues focus on one type of modification in an attempt to The N-acetylgalactosamine (GalNAc) delivery approach is an alternative to nanoparticles, 717 in which ligands are conjugated to RNA that permit them to enter target cells. Nair et al. 718 found a tertiary conjugation between GalNAc and RNA, which is perhaps the most advanced 13. Puttaraju, M., Jamison, S.F., Mansfield, S.G., Garcia-Blanco, M.A., and Mitchell, L.G.(1999 Wang, X., Arai, S., Song, X., Reichart, D., Du, K., Pascual, G., Tempst, P., Rosenfeld Thiazolidinediones expand body fluid volume through PPARgamma 774 stimulation of ENaC-mediated renal salt absorption The RNA moiety 776 of ribonuclease P is the catalytic subunit of the enzyme Potent and 778 specific genetic interference by double-stranded RNA in Caenorhabditis elegans Antisense oligonucleotides: modifications 781 and clinical trials RNA interference: a chemist's 783 perspective RNA therapeutics on the rise Structural gene identification and 787 mapping by DNA*mRNA hybrid-arrested cell-free translation Inhibition of Rous sarcoma virus replication 790 and cell transformation by a specific oligodeoxynucleotide Incorporation of positively charged 794 linkages into DNA and RNA backbones: a novel strategy for antigene and antisense agents The approved gene therapy drugs 797 worldwide: from 1998 to 2019 Simple RNA enzymes with new and highly specific 852 endoribonuclease activities Structural and ionic 854 requirements for self-cleavage of virusoid RNAs and trans self-cleavage of viroid RNA Nucleotide sequence and newly formed 857 phosphodiester bond of spontaneously ligated satellite tobacco ringspot virus RNA Hairpin' catalytic RNA model: evidence for 860 helices and sequence requirement for substrate RNA Simple RNA enzymes with new and highly specific 862 endoribonuclease activities Ribozyme-mediated trans-splicing of a 864 trinucleotide repeat Improved transfection 866 and new selectable markers for the rodent malaria parasite Plasmodium yoelii The development of genetic tools 869 for dissecting the biology of malaria parasites Ribozyme-mediated, multiplex CRISPR gene editing and 871 CRISPR interference (CRISPRi) in rodent-infectious Plasmodium yoelii Structure of the 70S ribosome complexed with mRNA and tRNA Recent insights into the structure and function of the 877 ribonucleoprotein enzyme ribonuclease P Potentandspecific geneticinterferenceby double-strandedRNAin Caenorhabditiselegans Role for a bidentate 882 ribonuclease in the initiation step of RNA interference Biochemical identification of 884 Argonaute 2 as the sole protein required for RNA-induced silencing complex activity Proc Passenger-strand 887 cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes MicroRNA genes 890 are transcribed by RNA polymerase II The nuclear RNase III Drosha initiates microRNA processing Nuclear Export of 894 MicroRNA Precursors Science MicroRNAs: small RNAs with a big role in gene regulation MicroRNAs accurately identify cancer tissue origin MicroRNAs in stress signaling and human disease Activating gene expression in mammalian cells with promoter-targeted duplex RNAs Research progress of saRNA activated tumor 957 suppressor gene p21 and applications of saRNA Direct gene transfer into mouse muscle in vivo Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-963 entrapped mRNA In vivo application of RNA leads to 965 induction of specific cytotoxic T lymphocytes and antibodies Personalized RNA mutanome vaccines 968 mobilize poly-specific therapeutic immunity against cancer Expression of therapeutic 971 proteins after delivery of chemically modified mRNA in mice Synthesis and application of a 973 chain-terminating dinucleotide mRNA cap analog A+U-rich instability elements differentially activate 975 5'-3' and 3'-5' mRNA decay At least six nucleotides preceding the AUG initiator codon enhance 977 translation in mammalian cells Tumor vaccination using 979 messenger RNA: prospects of a future therapy An RNA vaccine drives 982 immunity in checkpoint-inhibitor-treated melanoma Evaluation of the mRNA-1273 Vaccine 985 against SARS-CoV-2 in Nonhuman Primates Perspectives on RNA Vaccine 988 Candidates for COVID-19 mRNA vaccines -a new era in 990 vaccinology Recent Advances in mRNA Vaccines for Infectious 992 Diseases Chemically modified siRNA: tools and 994 applications Synthesis of a Dithymidine Dinuleotide 996 Containing a 3' : 5'-Internucleotidic Linkuge. <18.pdf> Cellular dynamics of RNA modification Chemical modification of siRNA 1000 bases to probe and enhance RNA interference Backbone Modification of Nucleic Acids: Synthesis Chemical modification and design of anti-miRNA 1006 oligonucleotides Antisense oligonucleotide pharmacokinetics and metabolism Silencing of microRNAs in vivo with 'antagomirs' Tolerance for mutations and 1012 chemical modifications in a siRNA Therapeutic silencing of an endogenous 1015 gene by systemic administration of modified siRNAs RNA 1017 interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids 1018 Res Nanotechnologies and controlled release systems for the 1020 delivery of antisense oligonucleotides and small interfering RNA Effect of unsaturated alkyl chains on transfection activity of poly(amidoamine) dendron-1024 bearing lipids Cell-1026 penetrating peptide-siRNA conjugate loaded YSA-modified nanobubbles for ultrasound 1027 triggered siRNA delivery Insight into the mechanism of the 1029 peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian 1030 cells Single acute-dose and repeat-doses toxicity 1032 of anti-HIV-1 PNA TAR-penetratin conjugate after intraperitoneal administration to mice Chirality Dependent Potency Enhancement and 1036 Structural Impact of Glycol Nucleic Acid Modification on siRNA Structural Rationalization of a Large Difference in RNA Affinity Despite a Small 1040 Difference in Chemistry between Two 2′O -Modified Nucleic Acid Analogues 2P-Carbohydrate modi¢cations in antisense oligonucleotide therapy: 1043 importance of conformation, con¢guration and conjugation Design of noninflammatory 1046 synthetic siRNA mediating potent gene silencing in vivo RNA targeting therapeutics: molecular mechanisms of 1048 antisense oligonucleotides as a therapeutic platform Inhibition of microRNA with antisense oligonucleotides miR-122 regulation of lipid metabolism revealed by in vivo 1053 antisense targeting siRNA relieves chronic neuropathic pain Chemical modification of gene 1058 silencing oligonucleotides for drug discovery and development Locked Nucleic Acid 1061 (LNA) Recognition of RNA: NMR Solution Structures of LNA:RNA Hybrids MicroRNA-21 Is an Antiapoptotic Factor in 1064 Human Glioblastoma Cells Unlocked nucleic acid--an RNA modification with broad 1066 potential Improvements in siRNA properties mediated by 20-deoxy-20-fluoro-b-D-1071 arabinonucleic acid (FANA) Positional Effect of Chemical Modifications on Short 1074 Interference RNA Activity in Mammalian Cells Improved targeting of miRNA with antisense oligonucleotides LNA-modified oligonucleotides mediate 1078 specific inhibition of microRNA function Locked Nucleic Acid): An RNA Mimic Forming Exceedingly Stable LNA:LNA Duplexes A direct comparison of anti-microRNA oligonucleotide 1083 potency In vitro optimization of 2'-OMe-4'-thioribonucleoside-modified 1086 anti-microRNA oligonucleotides and its targeting delivery to mouse liver using a liposomal 1087 nanoparticle Synthesis and properties of novel L-isonucleoside modified oligonucleotides and 1090 siRNAs Development of a 2',4'-BNA/LNA-based siRNA for Dyslipidemia and 1093 Assessment of the Effects of Its Chemical Modifications In Vivo Short locked nucleic acid antisense 1097 oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and 1098 non-human primates Enhancing the Therapeutic 1100 Delivery of Oligonucleotides by Chemical Modification and Nanoparticle Encapsulation Delivery of oligonucleotides with lipid 1103 nanoparticles siRNA Versus miRNA as Therapeutics 1105 for Gene Silencing Novel lipoproteoplex delivers Keap1 siRNA based 1108 gene therapy to accelerate diabetic wound healing Ionization behavior of amino lipids 1110 for siRNA delivery: determination of ionization constants, SAR, and the impact of lipid pKa on 1111 cationic lipid-biomembrane interactions Recent advances in the 1113 design, development, and targeting mechanisms of polymeric micelles for delivery of siRNA 1114 in cancer therapy amphiphilic copolymer micelles as nucleic acid carriers for enhanced transfection in 1117 rat spinal cord Multivalent N-acetylgalactosamine-1120 conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing Disposition and Pharmacology of a GalNAc3-conjugated 1124 ASO Targeting Human Lipoprotein (a) in Mice The current landscape of nucleic acid therapeutics Efficacy and safety of voretigene neparvovec (AAV2-1130 hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, 1131 controlled, open-label, phase 3 trial The authors declare no conflict of interest.